Editorials

Family Practice and the Elimination of Tuberculosis



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2000 May 1;61(9):2629-2631.

  Related Article

After an unprecedented increase in reported cases of tuberculosis in the United States that began in 1986, the disease has been brought under control. In 1999, the number of reported cases of tuberculosis declined to an all-time low of 17,528, and the country recommitted itself to the goal of tuberculosis elimination that was first announced in 1989.1 Although new tools, such as an improved, effective vaccine, will be needed to eliminate tuberculosis, much can be accomplished with the improved use of current technologies.

Among the available control measures, treatment of persons with active tuberculosis is of paramount importance, especially to decrease morbidity and mortality and prevent secondary transmission to others. However, in the United States, the majority of active cases of tuberculosis occur among those with latent tuberculosis infection acquired in the past. Thus, the treatment of persons with latent tuberculosis infection who are at high risk for developing active disease is also a critical component of the elimination strategy.

In recognition of the importance of latent disease, the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC) have recently issued a new statement titled, “Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection.”2 The salient points of these new recommendations are summarized in the review of tuberculosis diagnosis, treatment and prevention by Jerant and colleagues,3 published in this issue.

Hence, the diagnosis and treatment of latent tuberculosis infection should be of major concern to family physicians, and primary care physicians will play a significant role in the elimination of tuberculosis in the United States. New cases of tuberculosis largely occur among persons in two risk groups: those who have recently been infected and those with medical conditions that facilitate the progression of latent tuberculosis infection to active disease. It is persons in these groups who are the focus of the new guidelines for management of latent tuberculosis infection. The ATS and the CDC are calling for increased testing for latent tuberculosis infection, but they are focusing on persons in these risk groups and discouraging testing in those who are at lower risk.

Although treatment of persons with active tuberculosis will often remain the domain of public health departments and medical sub-specialists (pulmonologists and infectious disease subspecialists), targeted testing for latent infection and treatment of high-risk infected persons will increasingly become a function of private practice, community health centers and managed care plans. Several categories of patients are of particular relevance: persons who have recently immigrated to the United States from tuberculosis-endemic countries and those with high-risk medical conditions.

Forty percent of new cases of tuberculosis in the United States are in persons born in other countries who have reactivation of latent infections.4 These persons and those with the medical conditions listed in Table 1 of the review article by Jerant3 should be tested for latent infection. In addition, family physicians may see a large number of persons whose occupation places them at risk of tuberculosis and who are found to have latent tuberculosis infection.

A complete understanding of which persons should be treated and with what drug or drug regimen is essential, and the new ATS/CDC recommendations also highlight new guidelines for the treatment of latent tuberculosis infection. After repeated analysis of data from clinical trials of isoniazid for the treatment of latent infection, the statement concludes that nine months of treatment with isoniazid (INH) provides optimal benefit and is preferred for all categories of patients.5 Although considerable benefit is also provided by six months of isoniazid treatment, the nine-month regimen should be given to children, patients with human immunodeficiency virus (HIV) infection and those with radiographic evidence of previously untreated tuberculosis.

Based on recent data from clinical trials in HIV-infected persons, a new two-month regimen of rifampin (Rifadin) and pyrazinamide, both commonly used drugs for treating patients with active tuberculosis, appears to provide protection equivalent to that of isoniazid.6 This regimen is recommended for use in adults with or without HIV infection. The advantages of this much shorter treatment regimen must be balanced against the costs and higher incidence of minor side effects, but it may be especially useful in cases in which the longer course of isoniazid treatment has not proved feasible. Finally, treatment with rifampin alone for four months is also an acceptable regimen.

The guidelines on baseline testing and treatment monitoring have also been revised to emphasize clinical rather than laboratory monitoring.7 Clinical monitoring involves education of the patient about signs and symptoms of tuberculosis and drug toxicity, as well as careful questioning and repeated education at monthly intervals. Laboratory monitoring is indicated for HIV-infected persons, pregnant and postpartum women and those with a history of or risk factors for hepatic disease.

Changes in the epidemiology of tuberculosis and the new guidelines have set the stage for new opportunities in tuberculosis control. Risk assessment, targeted testing and implementation of new treatment regimens by primary care physicians will contribute significantly to the elimination of tuberculosis in the United States.

Dr. O'Brien is Chief of the Research and Evaluation Branch in the Division of Tuberculosis Elimination, National Center for HIV, TB, and STD Prevention, Centers for Disease Control and Prevention, Atlanta, Ga.

Dr. Cohn is Associate Director of Denver Public Health and Professor of Medicine in the Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver.

Address correspondence to Richard J. O'Brien, M.D., Division of Tuberculosis Elimination (E-10), National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333.

REFERENCES

1. Centers for Disease Control and Prevention. Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. Advisory Council for the Elimination of Tuberculosis (ACET). MMWR. 1999;48:1–13.

2. American Thoracic Society/Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000;161(Part 2):S221–47.

3. Jerant AF, Bannon M, Rittenhouse M. Identification and management of tuberculosis. Am Fam Physician. 2000;61:2667–78.

4. McKenna MT, McCray E, Onorato I. The epidemiology of tuberculosis among foreign-born persons in the United States, 1986 to 1993. N Engl J Med. 1995;332:1071–6.

5. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3:847–50.

6. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, et al. Rifampin and pyrazinamide vs. isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA. 2000;283:1445–50.

7. Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281:1014–8.


Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article